ghk-cu clinical trial wound healing randomized double blind Randomised, double-blind, placebo-controlled, parallel-group, multicentric, phase IIA for evaluating the safety, tolerability, and therapeutic efficacy of daily oral administration of NFX88 to treat neuropathic pain in individuals with Cagrilintide Therapy | Weight Quantity:1 L Energy & Wellness
Pay in 4 interest-free payments of $6.33 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 21 - Oct 26